Allakos Inc (NASDAQ:ALLK) has been given a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.
Brokerages have set a twelve-month consensus price target of $62.00 for the company and are predicting that the company will post ($0.34) EPS for the current quarter, according to Zacks. Zacks has also given Allakos an industry rank of 58 out of 256 based on the ratings given to related companies.
Separately, Zacks Investment Research raised Allakos from a “hold” rating to a “buy” rating and set a $38.00 price objective for the company in a report on Monday, October 15th.
NASDAQ ALLK traded down $1.05 during midday trading on Friday, hitting $43.95. The company had a trading volume of 227 shares, compared to its average volume of 472,850. Allakos has a twelve month low of $26.00 and a twelve month high of $65.48.
Allakos (NASDAQ:ALLK) last announced its quarterly earnings data on Thursday, November 8th. The company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.10). As a group, equities research analysts forecast that Allakos will post -1.22 EPS for the current fiscal year.
Allakos Company Profile
Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
Further Reading: Why is the ex-dividend date different from the record date?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.